SG Americas Securities LLC Acquires New Holdings in Nautilus Biotechnology, Inc. (NASDAQ:NAUT)

SG Americas Securities LLC bought a new stake in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 17,579 shares of the company’s stock, valued at approximately $50,000.

Other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Nautilus Biotechnology by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 2,859,402 shares of the company’s stock worth $8,407,000 after acquiring an additional 29,604 shares during the period. Renaissance Technologies LLC lifted its position in Nautilus Biotechnology by 11.2% in the second quarter. Renaissance Technologies LLC now owns 140,100 shares of the company’s stock worth $328,000 after purchasing an additional 14,100 shares during the period. Dimensional Fund Advisors LP boosted its stake in Nautilus Biotechnology by 19.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 574,844 shares of the company’s stock valued at $1,345,000 after purchasing an additional 94,908 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Nautilus Biotechnology by 35.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 16,078 shares of the company’s stock valued at $48,000 after purchasing an additional 4,239 shares during the period. Finally, Clarius Group LLC increased its position in shares of Nautilus Biotechnology by 2.7% during the 2nd quarter. Clarius Group LLC now owns 636,532 shares of the company’s stock valued at $1,489,000 after purchasing an additional 16,661 shares during the period. Institutional investors and hedge funds own 50.71% of the company’s stock.

Insider Buying and Selling

In related news, VP Mary E. Godwin sold 47,031 shares of the firm’s stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $2.87, for a total transaction of $134,978.97. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 40.50% of the company’s stock.

Nautilus Biotechnology Stock Down 1.4 %

Shares of Nautilus Biotechnology stock opened at $2.77 on Wednesday. The business has a fifty day simple moving average of $2.75 and a 200-day simple moving average of $2.62. Nautilus Biotechnology, Inc. has a fifty-two week low of $2.19 and a fifty-two week high of $3.45. The firm has a market cap of $346.98 million, a price-to-earnings ratio of -5.04 and a beta of 1.22.

Nautilus Biotechnology (NASDAQ:NAUT) last issued its quarterly earnings results on Tuesday, July 30th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.02. During the same quarter last year, the company earned ($0.13) earnings per share. Analysts anticipate that Nautilus Biotechnology, Inc. will post -0.65 earnings per share for the current fiscal year.

Nautilus Biotechnology Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.